Comparison of the efficacy and tolerability of BCG with and without interferon alpha 2b and/or megadose vitamin [Oncovite] supplements as adjuvant therapy in patients with non-muscle invasive bladder cancer (Ta, T1, or carcinoma in situ) who have received no prior BCG treatment for bladder cancer.

Trial Profile

Comparison of the efficacy and tolerability of BCG with and without interferon alpha 2b and/or megadose vitamin [Oncovite] supplements as adjuvant therapy in patients with non-muscle invasive bladder cancer (Ta, T1, or carcinoma in situ) who have received no prior BCG treatment for bladder cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Feb 2011

At a glance

  • Drugs BCG; Interferon alpha-2b; Vitamins
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top